The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Prostaglandin E2 Inhibits Alveolar Macrophage Phagocytosis through an E-Prostanoid 2 Receptor-Mediated Increase in Intracellular Cyclic AMP
Open accessAbstract
Prostaglandin E2 is a potent lipid mediator of inflammation that effects changes in cell functions through ligation of four distinct G protein-coupled receptors (E-prostanoid (EP)1, EP2, EP3, and EP4). During pneumonia, PGE2 production is enhanced. In the present study, we sought to assess the effect of endogenously produced and exogenously added PGE2 on FcRγ-mediated phagocytosis of bacterial pathogens by alveolar macrophages (AMs), which are critical participants in lung innate immunity. We also sought to characterize the EP receptor signaling pathways responsible for these effects. PGE2 (1–1000 nM) dose-dependently suppressed the phagocytosis by rat AMs of IgG-opsonized erythrocytes, immune serum-opsonized Klebsiella pneumoniae, and IgG-opsonized Escherichia coli. Conversely, phagocytosis was stimulated by pretreatment with the cyclooxygenase inhibitor indomethacin. PGE2 suppression of phagocytosis was associated with enhanced intracellular cAMP production. Experiments using both forskolin (adenylate cyclase activator) and rolipram (phosphodiesterase IV inhibitor) confirmed the inhibitory effect of cAMP stimulation. Immunoblot analysis of rat AMs identified expression of only EP2 and EP3 receptors. The selective EP2 agonist butaprost, but neither the EP1/EP3 agonist sulprostone nor the EP4-selective agonist ONO-AE1-329, mimicked the effects of PGE2 on phagocytosis and cAMP stimulation. Additionally, the EP2 antagonist AH-6809 abrogated the inhibitory effects of both PGE2 and butaprost. We confirmed the specificity of our results by showing that AMs from EP2-deficient mice were resistant to the inhibitory effects of PGE2. Our data support a negative regulatory role for PGE2 on the antimicrobial activity of AMs, which has important implications for future efforts to prevent and treat bacterial pneumonia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mortality by cause for eight regions of the world: Global Burden of Disease Study
Murray, C. J., & Lopez, A. D. (1997) · The Lancet · doi:10.1016/s0140-6736(96)07493-4 · Cited by 4,043
Prostaglandins as modulators of immunity
Harris, S. G., Padilla, J., Koumas, L., Ray, D., & Phipps, R. P. (2002) · Trends in Immunology · doi:10.1016/s1471-4906(01)02154-8 · Cited by 1,180
Prostanoid Receptors: Subtypes and Signaling
Breyer, R. M., Bagdassarian, C. K., Myers, S. A., & Breyer, M. D. (2001) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.41.1.661 · Cited by 1,011
Araki, N., Johnson, M. T., & Swanson, J. A. (1996) · The Journal of cell biology · doi:10.1083/jcb.135.5.1249 · Cited by 949 · cited 1×
“sRBCs (ICN Pharmaceuticals, Costa Mesa, CA) were opsonized with a subagglutinating concentration of polyclonal, rabbit anti-sRBC IgG (Cappel Organon Teknika, Durham, NC) as previously described (36).”
MethodRegulation of the immune response by prostaglandins
Goodwin, J. S., & Webb, D. R. (1980) · Clinical Immunology and Immunopathology · doi:10.1016/0090-1229(80)90024-0 · Cited by 768
Cyclooxygenase‐independent actions of cyclooxygenase inhibitors
Tegeder, I., Pfeilschifter, J., & Geisslinger, G. (2001) · The FASEB Journal · doi:10.1096/fj.01-0390rev · Cited by 747
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes
Tilley, S. L., Coffman, T. M., & Koller, B. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci200113416 · Cited by 726
Mixed messages: modulation of inflammation and immune responses by prostaglandins and thromboxanes
Tilley, S. L., Coffman, T. M., & Koller, B. H. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13416 · Cited by 725
Prostaglandin E2 regulates macrophage-derived tumor necrosis factor gene expression.
Kunkel, S. L., Spengler, M., May, M. A., Spengler, R., Larrick, J., & Remick, D. (1988) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)60727-6 · Cited by 661
Deaths: Preliminary Data for 2001: (566622006-001)
Arias, E., & Smith, B. L. (2003) · PsycEXTRA Dataset · doi:10.1037/e566622006-001 · Cited by 661
Cited by
Regulation of Immune Responses by Prostaglandin E2
Kalinski, P. (2012) · The Journal of Immunology · doi:10.4049/jimmunol.1101029 · Cited by 1,474
Proresolving Lipid Mediators and Mechanisms in the Resolution of Acute Inflammation
Buckley, C. D., Gilroy, D. W., & Serhan, C. N. (2014) · Immunity · doi:10.1016/j.immuni.2014.02.009 · Cited by 807
Kumar, V. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01722 · Cited by 684
The resolution of inflammation
Buckley, C. D., Gilroy, D. W., Serhan, C. N., Stockinger, B., & Tak, P. P. (2013) · Nature Reviews Immunology · doi:10.1038/nri3362 · Cited by 560
Koenigsknecht-Talboo, J., & Landreth, G. E. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1808-05.2005 · Cited by 477
Cirrhosis-associated immune dysfunction
Albillos, A., Martin-Mateos, R., Van der Merwe, S., Wiest, R., Jalan, R., & Álvarez-Mon, M. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00520-7 · Cited by 447
Cyclic AMP: Master Regulator of Innate Immune Cell Function
Serezani, C. H., Ballinger, M. N., Aronoff, D. M., & Peters-Golden, M. (2008) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0091tr · Cited by 415
Self-citationModulation of Macrophage Efferocytosis in Inflammation
Korns, D., Frasch, S. C., Fernandez-Boyanapalli, R., Henson, P. M., & Bratton, D. L. (2011) · Frontiers in Immunology · doi:10.3389/fimmu.2011.00057 · Cited by 349
Old and new generation lipid mediators in acute inflammation and resolution
Stables, M. J., & Gilroy, D. W. (2011) · Progress in Lipid Research · doi:10.1016/j.plipres.2010.07.005 · Cited by 334
Leukotrienes: Underappreciated Mediators of Innate Immune Responses
Peters-Golden, M., Canetti, C., Mancuso, P., & Coffey, M. J. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.2.589 · Cited by 329
Self-citationEfferocytosis Is an Innate Antibacterial Mechanism
Martin, C. J., Booty, M. G., Rosebrock, T. R., Nunes-Alves, C., Desjardins, D. M., Keren, I., Fortune, S. M., Remold, H. G., & Behar, S. M. (2012) · Cell Host & Microbe · doi:10.1016/j.chom.2012.06.010 · Cited by 285
Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2
O'Brien, A. J., Fullerton, J. N., Massey, K. A., Auld, G., Sewell, G., James, S., Newson, J., Karra, E., Winstanley, A., Alazawi, W., et al. (2014) · Nature Medicine · doi:10.1038/nm.3516 · Cited by 285
Scannell, M., Flanagan, M. B., deStefani, A., Wynne, K. J., Cagney, G., Godson, C., & Maderna, P. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4595 · Cited by 283
The Anti-Inflammatory Effects of Prostaglandins
Scher, J. U., & Pillinger, M. H. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31819aaa76 · Cited by 259
Dysfunctional Immune Response in Acute-on-Chronic Liver Failure: It Takes Two to Tango
Martin-Mateos, R., Alvarez-Mon, M., & Albillos, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00973 · Cited by 116
Prostaglandin E 2 as a Regulator of Immunity to Pathogens
Martínez-Colón, G. J., & Moore, B. B. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.12.008 · Cited by 109
Horino, T., Matsumoto, T., Uramatsu, M., Tanabe, M., Tateda, K., Miyazaki, S., Nakane, A., Iwakura, Y., & Yamaguchi, K. (2005) · Cytokine · doi:10.1016/j.cyto.2005.01.002 · Cited by 13
Metadata
- Authors
- Aronoff, D. M., Canetti, C., & Peters-Golden, M.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-07-01
- Volume
- 173
- Issue
- 1
- Pages
- 559-565
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1525044292
- Cited by
- 360
- References
- 40
- FWCI
- 8.99
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.